These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 19169894)

  • 41. A comparative immunohistochemical study of spontaneous and chemically induced pheochromocytomas in B6C3F1 mice.
    Hill GD; Pace V; Persohn E; Bresser C; Haseman JK; Tischler AS; Nyska A
    Endocr Pathol; 2003; 14(1):81-91. PubMed ID: 12746566
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Differential expression and processing of secretogranin II in relation to the status of pheochromocytoma: implications for the production of the tumoral marker EM66.
    Guillemot J; Thouënnon E; Guérin M; Vallet-Erdtmann V; Ravni A; Montéro-Hadjadje M; Lefebvre H; Klein M; Muresan M; Seidah NG; Anouar Y; Yon L
    J Mol Endocrinol; 2012 Apr; 48(2):115-27. PubMed ID: 22217803
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Identification of a key molecular regulator of liver metastasis in human pancreatic carcinoma using a novel quantitative model of metastasis in NOD/SCID/gammacnull (NOG) mice.
    Suemizu H; Monnai M; Ohnishi Y; Ito M; Tamaoki N; Nakamura M
    Int J Oncol; 2007 Oct; 31(4):741-51. PubMed ID: 17786304
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pheochromocytomas and paragangliomas: assessment of malignant potential.
    Korevaar TI; Grossman AB
    Endocrine; 2011 Dec; 40(3):354-65. PubMed ID: 22038451
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The microRNA expression changes associated with malignancy and SDHB mutation in pheochromocytoma.
    Patterson E; Webb R; Weisbrod A; Bian B; He M; Zhang L; Holloway AK; Krishna R; Nilubol N; Pacak K; Kebebew E
    Endocr Relat Cancer; 2012 Apr; 19(2):157-66. PubMed ID: 22241719
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Anthracyclines suppress pheochromocytoma cell characteristics, including metastasis, through inhibition of the hypoxia signaling pathway.
    Pang Y; Yang C; Schovanek J; Wang H; Bullova P; Caisova V; Gupta G; Wolf KI; Semenza GL; Zhuang Z; Pacak K
    Oncotarget; 2017 Apr; 8(14):22313-22324. PubMed ID: 28423608
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mastermind Like Transcriptional Coactivator 3 (MAML3) Drives Neuroendocrine Tumor Progression.
    Alzofon N; Koc K; Panwell K; Pozdeyev N; Marshall CB; Albuja-Cruz M; Raeburn CD; Nathanson KL; Cohen DL; Wierman ME; Kiseljak-Vassiliades K; Fishbein L
    Mol Cancer Res; 2021 Sep; 19(9):1476-1485. PubMed ID: 33986121
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas.
    Mete O; Asa SL; Gill AJ; Kimura N; de Krijger RR; Tischler A
    Endocr Pathol; 2022 Mar; 33(1):90-114. PubMed ID: 35285002
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pheochromocytomas in Nf1 knockout mice express a neural progenitor gene expression profile.
    Powers JF; Evinger MJ; Zhi J; Picard KL; Tischler AS
    Neuroscience; 2007 Jul; 147(4):928-37. PubMed ID: 17582688
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Use of fusion images of I-131 metaiodobenzylguanidine, SPECT, and magnetic resonance studies to identify a malignant pheochromocytoma.
    Fujita A; Hyodoh H; Kawamura Y; Kanegae K; Furuse M; Kanazawa K
    Clin Nucl Med; 2000 Jun; 25(6):440-2. PubMed ID: 10836692
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Malignant pheochromocytoma with hepatic metastasis diagnosed 10 years after a resection of the primary incidentaloma adrenal lesion: report of a case.
    Morikawa T; Suzuki M; Unno M; Endo K; Katayose Y; Matsuno S
    Surg Today; 2001; 31(1):80-4. PubMed ID: 11213051
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Metastatic pheochromocytoma associated with multiple endocrine neoplasia syndrome type II.
    Chevinsky AH; Minton JP; Falko JM
    Arch Surg; 1990 Jul; 125(7):935-8. PubMed ID: 1695090
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Identification of the secretogranin II-derived peptide EM66 in pheochromocytomas as a potential marker for discriminating benign versus malignant tumors.
    Yon L; Guillemot J; Montero-Hadjadje M; Grumolato L; Leprince J; Lefebvre H; Contesse V; Plouin PF; Vaudry H; Anouar Y
    J Clin Endocrinol Metab; 2003 Jun; 88(6):2579-85. PubMed ID: 12788858
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Generation of MCF-7 cells with aggressive metastatic potential in vitro and in vivo.
    Ziegler E; Hansen MT; Haase M; Emons G; Gründker C
    Breast Cancer Res Treat; 2014 Nov; 148(2):269-77. PubMed ID: 25292421
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Histological grading of adrenal and extra-adrenal pheochromocytomas and relationship to prognosis: a clinicopathological analysis of 116 adrenal pheochromocytomas and 30 extra-adrenal sympathetic paragangliomas including 38 malignant tumors.
    Kimura N; Watanabe T; Noshiro T; Shizawa S; Miura Y
    Endocr Pathol; 2005; 16(1):23-32. PubMed ID: 16000843
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prognostic markers in pheochromocytoma.
    Clarke MR; Weyant RJ; Watson CG; Carty SE
    Hum Pathol; 1998 May; 29(5):522-6. PubMed ID: 9596278
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Differential diagnosis of pheochromocytomas and paragangliomas.
    McNichol AM
    Endocr Pathol; 2001; 12(4):407-15. PubMed ID: 11914474
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long intergenic noncoding RNA profiles of pheochromocytoma and paraganglioma: A novel prognostic biomarker.
    Ghosal S; Das S; Pang Y; Gonzales MK; Huynh TT; Yang Y; Taieb D; Crona J; Shankavaram UT; Pacak K
    Int J Cancer; 2020 Apr; 146(8):2326-2335. PubMed ID: 31469413
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Neuroendocrine markers and sustentacular cell count in benign and malignant pheochromocytomas - a comparative study.
    Białas M; Okoń K; Dyduch G; Ciesielska-Milian K; Buziak M; Hubalewska-Dydejczyk A; Sobrinho-Simoes M
    Pol J Pathol; 2013 Jun; 64(2):129-35. PubMed ID: 23900871
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Igf-I regulates pheochromocytoma cell proliferation and survival in vitro and in vivo.
    Fernández MC; Venara M; Nowicki S; Chemes HE; Barontini M; Pennisi PA
    Endocrinology; 2012 Aug; 153(8):3724-34. PubMed ID: 22653556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.